Next up on the list is a company that I happen to work with on a daily basis, Becton , Dickinson and Company (NYSE: BDX ). Company and Industry Overview : Becton , Dickinson and Company is a global medical technology company focused on the design
By Mark Chapman : It has now been about 6 months since I penned an article about Antares Pharma (NASDAQ: ATRS ) suggesting that Otrexup alone should make the stock worth $5.10. Considering that the stock market is forward looking, and not a single one of my potential catalysts came to fruition, I
By Dividends4Life : Linked here is a detailed quantitative analysis of Medtronic Inc. (NYSE: MDT ). Below are some highlights from the above linked analysis: Company Description: Medtronic Inc. is a global medical device manufacturer has leadership positions in the pacemaker, defibrillator, ...
important event in patent litigation. The company has outstanding patent disputes with Abbott Labs, Affymetrix, Agilent, Becton Dickinson, Gen-Probe, Hologic, Ilumina, Life Technologies, Luminex, Roche and Seimens. Post your comment!
Becton Dickinson reported third-quarter results, and its year-to-date numbers track slightly ahead our forecast. We're raising
Becton Dickinson reported second-quarter results and slightly raised its EPS guidance for the full year. The revised estimate is in
Hello, and welcome to BD's Second Fiscal Quarter 2014 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through May 8, 2014, on the Investors page of the bd.com website or by phone at 800-585-8967 for domestic calls and area code 404-537-3406 for
Becton Dickinson reported fiscal first-quarter results on Tuesday and raised the lower end of its 2014 projections, both of which fell
Becton Dickinson reported fiscal fourth-quarter results and provided its 2014 outlook, which both were within our range of expectations
Sept 20 (Reuters) - Becton Dickinson and Co said it may have to pay up to $340 million after a federal jury found the medical device maker guilty of attempting to monopolize the safety syringe market...